{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:40:28Z","timestamp":1775151628490,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12,15]]},"DOI":"10.1097\/qai.0b013e318158bec9","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T01:25:30Z","timestamp":1236216330000},"page":"581-589","source":"Crossref","is-referenced-by-count":35,"title":["A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy"],"prefix":"10.1097","volume":"46","author":[{"given":"Dianne L","family":"Carey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Easey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"Machon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210131","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","article-title":"Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.","volume":"28","author":"Ammassari","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R2-9-20210131","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","article-title":"Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.","volume":"15","author":"Duran","year":"2001","journal-title":"AIDS"},{"key":"R3-9-20210131","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/383573","article-title":"Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1.","volume":"38","author":"Blanch","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R4-9-20210131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"R5-9-20210131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R6-9-20210131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-9-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to Combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.","volume":"33","author":"John","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-9-20210131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study.","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"R9-9-20210131","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"R10-9-20210131","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"R11-9-20210131","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/01.aids.0000180106.11383.cc","article-title":"Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.","volume":"19","author":"Carey","year":"2005","journal-title":"AIDS"},{"key":"R12-9-20210131","first-page":"1279","article-title":"Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.","volume":"30","author":"Jones","year":"2004","journal-title":"Dermatol Surg"},{"issue":"Suppl","key":"R13-9-20210131","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1086\/426686","article-title":"Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.","volume":"40","author":"Guaraldi","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R14-9-20210131","first-page":"19","article-title":"Bioabsorbable plates and screws: current state of the art in facial fracture repair.","volume":"6","author":"Suuronen","year":"2000","journal-title":"J Craniomaxillofac Trauma"},{"key":"R15-9-20210131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00431041","article-title":"Ciprofloxacin-impregnated poly-L-lactic acid drug carrier. New aspects of a resorbable drug delivery system in local antimicrobial treatment of bone infections.","volume":"112","author":"Teupe","year":"1992","journal-title":"Arch Orthop Trauma Surg"},{"key":"R16-9-20210131","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jbm.820270904","article-title":"Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB\/VA).","volume":"27","author":"Gogolewski","year":"1993","journal-title":"J Biomed Mater Res"},{"key":"R17-9-20210131","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1097\/00002030-200311210-00009","article-title":"Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.","volume":"17","author":"Valantin","year":"2003","journal-title":"AIDS"},{"key":"R18-9-20210131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2004.00190.x","article-title":"A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.","volume":"5","author":"Moyle","year":"2004","journal-title":"HIV Med"},{"key":"R19-9-20210131","first-page":"1336","article-title":"Safety and efficacy of poly-L-lactic acid injections in patients with HIV-associated facial lipoatrophy: the US experience.","volume":"32","author":"Mest","year":"2006","journal-title":"Dermatol Surg"},{"key":"R21-9-20210131","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaad.2004.08.056","article-title":"Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.","volume":"52","author":"Burgess","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R22-9-20210131","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.qai.0000152834.02912.98","article-title":"Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients.","volume":"38","author":"Lafaurie","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-9-20210131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archderm.142.3.329","article-title":"Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.","volume":"142","author":"Cattelan","year":"2006","journal-title":"Arch Dermatol"},{"key":"R24-9-20210131","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350501000606","article-title":"Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.","volume":"10","author":"Guaraldi","year":"2005","journal-title":"Antivir Ther"},{"key":"R25-9-20210131","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1089\/apc.2006.20.829","article-title":"Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.","volume":"20","author":"Negredo","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"R27-9-20210131","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00126334-200308150-00004","article-title":"An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score.","volume":"33","author":"Carr","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-9-20210131","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"R29-9-20210131","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R30-9-20210131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS-36 Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"R32-9-20210131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/09540120412331305098","article-title":"Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.","volume":"17","author":"Mannheimer","year":"2005","journal-title":"AIDS Care"},{"key":"R33-9-20210131","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1086\/339074","article-title":"The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.","volume":"34","author":"Mannheimer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R34-9-20210131","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","article-title":"The validity and practicality of sun-reactive skin types I through VI.","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"key":"R35-9-20210131","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"R36-9-20210131","first-page":"546","article-title":"Psychosocial impact of the lipodystrophy syndrome in HIV infection.","volume":"10","author":"Collins","year":"2000","journal-title":"AIDS Read"},{"key":"R37-9-20210131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1468-1293.2006.00342.x","article-title":"Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.","volume":"7","author":"Moyle","year":"2006","journal-title":"HIV Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200712150-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:19:18Z","timestamp":1684912758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200712150-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,15]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318158bec9","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12,15]]}}}